| Primary | Achievement of the JNC 7 Treatment Goals (BP <140/90 mmHg) at Week 52 | The proportion of patients enrolled in the study who achieve the JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) treatment goals (blood pressure (BP) <140/90 mmHg) in a primary-care setting at week 52. This variable was derived from the mean sitting blood pressure assessed by the investigators at week 52. To achieve JNC 7 treatment goals, the subject had to satisfy both blood pressure criteria - systolic blood pressure below 140 mm Hg and diastolic blood pressure below 90 mm Hg. | ITT dataset which included all patients, who received at least one dose of study medication. | Posted | | Number | | Percentage of participants | | Up to 52 weeks | | | | ID | Title | Description |
|---|
| OG000 | All Subjects | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. |
| | | Title | Denominators | Categories |
|---|
| Yes | | | | No | | |
| |
| Secondary | Achieving JNC 7 Treatment Goals After Ramadan | The proportion of patients enrolled in the study who achieve the JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) treatment goals (blood pressure (BP) <140/90 mmHg) in a primary-care setting after Ramadan. This variable was derived from the mean sitting blood pressure assessed by the investigators after Ramadan. To achieve JNC 7 treatment goals, the subject had to satisfy both blood pressure criteria - systolic blood pressure below 140 mm Hg and diastolic blood pressure below 90 mm Hg. | Per-protocol (PP) population which included all eligible patients who did not experience any protocol violation and were treated with the study medication up to week 52 (study completers) according to the prescribing information. | Posted | | Number | | Percentage of participants | | 1 month | | | | ID | Title | Description |
|---|
| OG000 | Fasting | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. Patients who did fast for Ramadan. | | OG001 | Non-Fasting | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. Patients who did not fast for Ramadan. |
|
| Secondary | Cardiovascular Events | Percentage of participants who experienced a major cardiovascular (CV) event | All subjects included in the study according to the study protocol i.e. patients who did not violate any inclusion or exclusion criteria | Posted | | Number | | Percentage of participants | | Up to 52 weeks | | | | ID | Title | Description |
|---|
| OG000 | All Subjects | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. |
| |
| Secondary | The Overall Assessment of Treatment by Patients at 52 Weeks | The overall assessment of treatment by patients at 52 weeks. Assessed using a verbal rating scale with 5 categories: Outstanding, very satisfactory, satisfactory, marginal and not satisfactory. | | Posted | | Number | | Percentage of participants | | Up to 52 weeks | | | | ID | Title | Description |
|---|
| OG000 | All Subjects | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. |
| |
| Secondary | The Overall Assessment of Treatment by Physicians at 52 Weeks | The overall assessment of treatment by physicians at 52 weeks. Assessed using a verbal rating scale with 5 categories: Outstanding, very satisfactory, satisfactory, marginal and not satisfactory. | | Posted | | Number | | Percentage of participants | | Up to 52 weeks | | | | ID | Title | Description |
|---|
| OG000 | All Subjects | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. |
| |
| Secondary | Compliance of Patients up to 10 Days Before Ramadan | Compliance of patients up to 10 days before ramadan (treated by internists and cardiologists as primary physician). Subjects were asked how often they have not taken their medicine and were given five possible choices from "none of the time" to "all of the time". | Per-protocol population including all patients with data 10 days before Ramadan | Posted | | Number | | Percentage of participants | | 10 days before Ramadan | | | | ID | Title | Description |
|---|
| OG000 | All Subjects | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. |
| |
| Secondary | Compliance of Patients up to 10 Days After Ramadan | Compliance of patients up to 10 days after Ramadan (treated by internists and cardiologists as primary physician). Subjects were asked how often they have not taken their medicine and were given five possible choices from "none of the time" to "all of the time". | Per-protocol population including all patients with data 10 days after Ramadan | Posted | | Number | | Percentage of participants | | 10 days after Ramadan | | | | ID | Title | Description |
|---|
| OG000 | All Subjects | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. |
| |
| Secondary | Compliance of Patients During the Whole Study Duration (52 Weeks) | Compliance of patients during the whole study duration (treated by internists and cardiologists as primary physician). Subjects were asked how often they have not taken their medicine and were given five possible choices from "none of the time" to "all of the time". | Per-protocol population including all patients with data at 52 weeks | Posted | | Number | | Percentage of participants | | Up to 52 weeks | | | | ID | Title | Description |
|---|
| OG000 | All Subjects | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. |
| |
| Secondary | Achievement of the JNC 7 Treatment Goals During the Whole Study Duration (Treated by Internists and Cardiologists as Primary Physician) | Proportion of patients who achieved the JNC 7 treatment goals during the whole study duration (treated by internists and cardiologists as primary physician) | | Posted | | Number | | Percentage of participants | | Up to 52 weeks | | | | ID | Title | Description |
|---|
| OG000 | Cardiologist | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. Patients whose primary physician was a cardiologist. | | OG001 | Internist | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. Patients whose primary physician was a internist. |
| |
| Secondary | The Difference in Systolic Blood Pressure Before and After the Month of Ramadan | Change from baseline in systolic blood pressure before and after the month of Ramadan | | Posted | | Mean | Standard Deviation | mmHg | | Baseline, 10 days before Ramadan, 10 days after Ramadan and 52 weeks | | | | ID | Title | Description |
|---|
| OG000 | Fasting | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. Patients who did fast for Ramadan. | | OG001 | Non-Fasting | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. Patients who did not fast for Ramadan. |
| |
| Secondary | The Difference in Diastolic Blood Pressure Before and After the Month of Ramadan | Change from baseline in diastolic blood pressure before and after the month of Ramadan | | Posted | | Mean | Standard Deviation | mmHg | | Baseline, 10 days before Ramadan, 10 days after Ramadan and 52 weeks | | | | ID | Title | Description |
|---|
| OG000 | Fasting | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. Patients who did fast for Ramadan. | | OG001 | Non-Fasting | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. Patients who did not fast for Ramadan. |
| |
| Secondary | The Percentage of Patients Achieving JNC 7 Treatment Goals at the End of the 1 Year Treatment Duration | The proportion of patients enrolled in the study who achieve the JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) treatment goals (blood pressure (BP) <140/90 mmHg) in a primary-care setting at the end of the 1 year treatment duration. This variable was derived from the mean sitting blood pressure assessed by the investigators at the end of the 1 year treatment duration. To achieve JNC 7 treatment goals, the subject had to satisfy both blood pressure criteria - systolic blood pressure below 140 mm Hg and diastolic blood pressure below 90 mm Hg. At this timepoint, a diagnosis of diabetes mellitus and/or kidney disease was also taken into account. Subjects with either of the mentioned conditions had to have systolic blood pressure lower than 130 mm Hg and diastolic blood pressure below 80 mm Hg to satisfy JNC 7 treatment goals. | | Posted | | Number | | Percentage of participants | | Up to 52 weeks | | | | ID | Title | Description |
|---|
| OG000 | All Subjects | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. |
| |
| Secondary | Adverse Events Under Angiotensin II (Type 1) Receptor Blockers (ARBs) Treatment When Given in Combination With Calcium-Channel Blockers (CCBs) | Number of participants with adverse events in participants receiving Angiotensin II (Type 1) Receptor Blockers (ARBs) when given in combination with Calcium-Channel Blockers (CCBs) during the whole study duration. | All subjects who took a combination of ARB and CCB drugs. | Posted | | Number | | participants | | Up to 52 weeks | | | | ID | Title | Description |
|---|
| OG000 | All Subjects | Newly diagnosed or uncontrolled adult hypertensive patients with at least one cardiovascular risk factor who are prescribed antihypertensive drugs with an approved indication for cardiovascular protection (including Micardis® 80 mg/ Micardis® Plus tablets) as monotherapy or as part of a combination regimen with other antihypertensive agents. Treatment duration is up to 52 weeks. |
| |